Diaceutics and Throtle Announce Strategic Collaboration to Enhance Healthcare Data Enrichment
Sarah Heming
We are delighted to announce our latest partnership with Throtle! Our latest collaboration sets out to enhance healthcare data enrichment. Throtle is the healthcare industry’s dedicated identity provider of privacy-compliant identity resolution capabilities. We are a leading technology and solutions provider to the pharmaceutical and biotech industry.
This partnership integrates Throtle’s privacy-compliant identity resolution capabilities with our data. Together, we will help life sciences organizations engage HCPs with greater precision and efficiency.
The healthcare landscape is constantly evolving and demands accurate, data-driven marketing. We will leverage Throtle’s identity resolution to unify fragmented data sources. This will help deliver more meaningful insights across the HCP journey. Our partnership will empower pharma organizations to execute more targeted and effective omnichannel strategies that drive measurable outcomes.
“Identity resolution is a cornerstone of modern healthcare marketing. We are excited to support Diaceutics in advancing personalized HCP engagement while maintaining the highest standards of data privacy and compliance.”
– Maggie Jordan, Chief Strategy Officer, Throtle.
We're incorporating rich laboratory test results and genomic profiles. This enables pharmaceutical brands to activate HCP audiences by focusing on patient journeys at the molecular level. Furthermore, this allows for unprecedented precision in marketing efforts.
“We’ve built a strong foundation in delivering best-in-class commercialization strategies. These are powered by data, diagnostics, and precision medicine expertise.
Our collaboration with Throtle marks an important step forward. It will enhance our ability to activate precision medicine data with unparalleled accuracy. By strengthening our identity resolution capabilities, we are fundamentally reshaping how brands connect with HCPs across digital channels.”
– Scott Phillips, VP of Real World Data, Diaceutics.
Our collaboration aims to set a new standard for HCP engagement and healthcare data enrichment in the pharma and biotech space. We look forward to helping pharmaceutical organizations achieve more.
About Diaceutics
Our ethos is that every patient deserves access to the right tests and therapies, for the best possible disease outcome. For close to 20 years, we have worked with the world’s top pharma and biotechs. Our specialism is in delivering precision medicine and diagnostic solutions. By utilizing our daily lab, genomic, claims, EHR, and pharmacy data, we enable our partners to improve HCP media targeting and revolutionize campaigns.
About Throtle
Throtle is a healthcare identity resolution company trusted by healthcare brands and agencies. They help clients identify, activate, and measure their customer and prospect campaigns. This, in turn, helps accurately discover which channels and devices they can be reached.
Their identity solutions are the core to successful healthcare marketing initiatives. This helps identify the largest, most impactful audiences to drive better outcomes faster.
Throtle understands the delicate balance of data-driven marketing within the healthcare sector. These powerful identity solutions combine innovation with industry compliance. You can empower your organization to validate patients and HCPs securely with Throtle. Partner up and turn data into actionable audiences with identity-driven solutions. Supercharge your marketing initiatives.
About Diaceutics
We’ve been with pharma and biotech companies for over 20 years, helping them to make more informed diagnostic and therapeutic decisions based on real-world data. Our platforms and tools provide global insight from a network of laboratories across 50+ countries.
This unparalleled visibility into real-world testing helps support therapy programs across oncology, cardiology, neurology, autoimmune, rare diseases, and many more.
What is the D-Cubed model in pharma commercialization?
D-Cubed is a different operating model for pharmaceutical commercialization. Diagnostics trigger demand, data compounds advantage, and digital delivers engagement at scale. It is a playbook that moves beyond legacy launch tactics.
How do pharma companies industrialize the D-Cubed model?
Five steps are required:
- Put diagnostics in the lead
- Make data the connective tissue
- Deliver digital services that convert more than 80% of patients onto drug
- Experiment boldly with test-triggered pilots
- Platformize for steep economies of scale
What external forces are driving D-Cubed adoption in pharma?
Pharma is no longer the only determinant of how fast D-Cubed is adopted. Seven external forces are reshaping the landscape:
- AI raising expectations for faster, more precise commercial execution
- Policy and payers tying reimbursement to testing
- Patients empowered by genomics and portable health data
- Regulators approving more therapies only with diagnostics
- Capital markets demanding better ROI
- Health systems rolling out national genomic programs
- Tech entrants embedding diagnostics into consumer platforms
How can peer-to-peer education improve diagnostic adoption in rare oncology?
In rare oncology, low testing familiarity and clinical hesitation can delay adoption. One global pharma organization paired diagnostics-triggered data with trusted peer-to-peer education. Real-world diagnostic signals identified when physicians were likely to encounter eligible patients. Expert Exchange then activated practicing experts to deliver tailored, case-based sessions within 48 hours.
What results has Expert Exchange delivered?
Why does acting early on the D-Cubed model matter for pharma?
Written By Sarah Heming
Newsletter sign up
READY TO DO COMMERCIALIZATION DIFFERENTLY?
You might also be interested in?
Amplifying Your Precision Medicine Strategy: The role of Engagement Experts and Peer Networks
Enhance your precision medicine strategy through multi-modal communications and peer engagement, driving effective diagnostic commercialization and maximizing patient outcomes.